Based on the provided financial report, the title of the article is: "DRUGS MADE IN AMERICA ACQUISITION II CORP. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026
Based on the provided financial report, the title of the article is: "DRUGS MADE IN AMERICA ACQUISITION II CORP. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2026
The quarterly report for Drugs Made in America Acquisition II Corp. (DMIIU) for the period ended June 30, 2026, shows a net loss of $1.4 million for the three months ended June 30, 2026, compared to a net loss of $1.1 million for the same period in 2025. The company’s total assets decreased to $1.3 million as of June 30, 2026, from $1.6 million as of December 31, 2025. The company’s cash and cash equivalents decreased to $1.1 million as of June 30, 2026, from $1.4 million as of December 31, 2025. The company’s ordinary shares outstanding as of August 14, 2026, were 63,700,000. The report also includes the company’s balance sheets, statements of operations, statements of changes in shareholders’ deficit, and statements of cash flows for the three and six months ended June 30, 2026, and 2025.
Overview
Drugs Made In America Acquisition Corp. is a blank check company formed in 2024 for the purpose of completing a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company is focused on identifying and acquiring a target in the pharmaceutical industry.
The company completed its initial public offering (IPO) in September 2025, raising $500 million by selling 50 million units at $10 per unit. Each unit consists of one ordinary share and one right to receive one-tenth of an ordinary share upon the completion of an initial business combination. Simultaneously, the company sold 1.2 million private placement units to the sponsor and underwriter for $12 million.
The net proceeds from the IPO and private placement were placed in a trust account, which the company intends to use to fund its initial business combination. The company has up to 24 months from the IPO to complete a business combination, after which it will be required to redeem 100% of its public shares if a deal is not reached.
Financial Performance
Since its inception in August 2024 through June 2026, the company has not engaged in any operations or generated any revenue. Its only activities have been organizational, preparing for the IPO, and searching for a suitable business combination target.
For the three months ended June 30, 2026, the company reported net income of $4.4 million, consisting of $4.5 million in interest earned on the trust account assets, offset by $112,227 in general and administrative expenses.
For the six months ended June 30, 2026, the company reported net income of $8.7 million, consisting of $8.9 million in interest earned on the trust account assets, a $30,000 gain from the recovery of credit losses, offset by $244,257 in general and administrative expenses.
In comparison, the company reported net losses of $38,073 and $97,400 for the three and six months ended June 30, 2025, respectively, consisting entirely of general and administrative costs.
Liquidity and Capital Resources
As of June 30, 2026, the company had $174,974 in cash. Prior to the IPO, the company’s only source of liquidity was an initial purchase of ordinary shares by the sponsor and loans from the sponsor.
After the IPO, the company has $500 million in trust account assets, which it intends to use to fund the initial business combination. The company may also seek additional financing, either to complete the business combination or if it becomes obligated to redeem a significant number of public shares.
The company does not believe it will need to raise additional funds to meet its operating expenses prior to the business combination. However, the company has noted that if its estimate of the costs to identify a target, conduct due diligence, and negotiate the deal are less than the actual amount required, it may not have sufficient funds available.
Going Concern
The company has acknowledged that the conditions related to its ability to complete an initial business combination within the 24-month time frame raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty.
Contractual Obligations
The company’s only significant contractual obligation is the deferred underwriting fee of $17.5 million (or $21.6 million if the over-allotment option is exercised) payable to the underwriters upon completion of the initial business combination.
Critical Accounting Estimates
The company has not identified any critical accounting estimates in preparing its unaudited financial statements.
Outlook
Drugs Made In America Acquisition Corp. faces the challenge of identifying and completing a suitable business combination within the 24-month time frame. The company’s success will depend on its ability to find an attractive target in the pharmaceutical industry and negotiate a deal that creates value for shareholders. Failure to complete a business combination within the allotted time could result in the company being forced to redeem its public shares and cease operations.